Atrophic Vaginitis in Breast or Endometrial Cancer: When Non-Hormonal Vaginal Therapy Has Not Relieved Dryness

This protocol addresses atrophic vaginitis in women with a history of hormone-sensitive malignancy — specifically breast cancer or endometrial cancer — where first-line non-hormonal treatment has not achieved the goal of vaginal dryness relief.

Clinical scenario

The patient has a history of a hormone-sensitive malignancy — breast cancer or endometrial cancer. Because of this oncological background, treatment selection must account for the potential implications of hormonal therapies, and non-hormonal options are typically considered first.

Prior treatment — insufficient response

Non-hormonal vaginal moisturizer treatments and vaginal lubricants used during intercourse represent the standard first approach in this setting. In this case, these measures have not achieved the therapeutic goal of relief of vaginal dryness, and escalation to the next step is indicated.

This protocol applies when non-hormonal first-line measures have been tried and found to be insufficient.

Next-line approach

In this specific context, a vaginal estrogen-based approach may be considered — with particular attention to patient counselling given the underlying oncological history. The complete regimen, eligibility criteria, and clinical guidance are available in the full protocol.

Treatment goal

Relief of vaginal dryness.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3109/13697137.2010.522875

Non-hormonal options are primarily indicated in women wishing to avoid hormonal therapy or in high-risk individuals with a history of hormone-sensitive malignancy such as breast or endometrial cancer.

For women with breast cancer, non-hormonal therapies are preferred but, where these are ineffective, vaginal estrogens can be used at the lowest effective dose with appropriate patient counselling.

View source ↗